Results 181 to 190 of about 6,468 (198)

Dinucleotide codon substitutions as a signature of diversifying selection in <i>Mycobacterium tuberculosis</i>. [PDF]

Front Mol Biosci
Zimenkov D, Ushtanit A.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy, 1997
Pyrazinamide (PZA) is a first-line drug for short-course tuberculosis therapy. Resistance to PZA is usually accompanied by loss of pyrazinamidase (PZase) activity in Mycobacterium tuberculosis. PZase converts PZA to bactericidal pyrazinoic acid, and the loss of PZase activity is associated with PZA resistance.
A, Scorpio, P, Lindholm-Levy, L, Heifets, R, Gilman, S, Siddiqi, M, Cynamon, Y, Zhang   +6 more
openaire   +2 more sources

Drug resistance mechanism of PncA inMycobacterium tuberculosis

Journal of Biomolecular Structure and Dynamics, 2013
Tuberculosis continues to be a global health threat. Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis treatment. The emergence of strains resistant to PZA represents an important public health problem, as both first- and second-line treatment regimens include PZA. It becomes toxic to Mycobacterium tuberculosis when
Vidya, Rajendran, Rao, Sethumadhavan
openaire   +2 more sources

Crystal structure of the nicotinamidase/pyrazinamidase PncA from Bacillus subtilis

Biochemical and Biophysical Research Communications, 2018
The nicotinamidase/pyrazinamidase PncA is a member of a large family of hydrolase enzymes that catalyze the deamination of nicotinamide to nicotinic acid. PncA also functions as a pyrazinamidase in a wide variety of eubacteria and is an essential coenzyme in many cellular redox reactions in living systems.
Fei Shang, Jinli Chen, Lulu Wang, Liming Jin, Linhai Zou, Tingting Bu, Yuesheng Dong, Nam-Chul Ha, Ki Hyun Nam, Chunshan Quan, Yongbin Xu   +10 more
openaire   +2 more sources

Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis

Journal of Medical Microbiology, 2005
Drug-resistant Mycobacterium tuberculosis poses a significant threat to the treatment of tuberculosis (TB). The current susceptibility testing for the first-line TB drug pyrazinamide (PZA) is not only time-consuming but also difficult, due to the requirement for acid pH for drug activity. Predominantly, resistance to PZA in M. tuberculosis is caused by
Steven, Denkin, Dmitriy, Volokhov, Vladimir, Chizhikov, Ying, Zhang   +3 more
openaire   +2 more sources

The pncA gene mutations of Mycobacterium tuberculosis in multidrug‐resistant tuberculosis

Biotechnology and Applied Biochemistry, 2021
AbstractThe pncA gene encodes pyrazinamidase enzyme which converts drug pyrazinamide to active form pyrazinoic acid, but mutations in this gene can prevent enzyme activity which leads to pyrazinamide resistance. The cross‐sectional study was carried out during 2016–2017 for 12 months.
Nasir Mahmood, Sadia Bhatti, Shahzada Nadeem Abbas, Saman Shahid, Sarah Bushra Nasir   +4 more
openaire   +2 more sources

Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis

Molecular Diagnosis, 1998
The gene coding for pyrazinamidase (PZase) activity, pncA, in Mycobacterium tuberculosis was recently cloned, and several mutations which correlate with in vitro resistance to pyrazinamide (PZA) have been identified. During the development of a clinical molecular assay for the detection of PZA resistance, two previously unreported mutations in isolates
B SACHAIS, I NACHAMKIN, J MILLS, D LEONARD   +3 more
openaire   +1 more source

A Preliminary Report of Parent/Nurse-controlled Analgesia (PNCA) in Infants and Preschoolers

The Clinical Journal of Pain, 2011
infants and young children are often unable to verbalize pain or advocate for themselves which may increase their risk for poor pain assessment and management. Although patient-controlled analgesia (PCA) has been shown to be safe, effective, and superior to intermittent opioid dosing, infants and young children are not able to operate PCA independently.
Michelle L, Czarnecki, Katherine S, Salamon, Kristen E, Jastrowski Mano, Antonella S, Ferrise, Mickel, Sharp, Steven J, Weisman   +5 more
openaire   +2 more sources

Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand

Pathology, 2009
To describe the molecular basis of pyrazinamide (PZA) resistance among Mycobacterium tuberculosis in New Zealand, and to compare the pncA gene sequence among isolates with phenotypic (Bactec 960 and Wayne's assay) evidence of PZA resistance.The pncA gene of 26 clinical isolates of M.
Sushil, Pandey, Sandie, Newton, Arlo, Upton, Sally, Roberts, Dragana, Drinković   +4 more
openaire   +2 more sources